Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neogen Corporation SEC filings document material events for an operating company focused on food safety and animal safety products. Recent 8-K filings cover quarterly results and financial condition, Regulation FD disclosures related to Petrifilm manufacturing validation, and exhibits containing earnings releases and business updates.
The company’s filings also record governance and leadership matters, including executive appointments and departures, compensatory arrangements, board committee assignments, annual meeting voting results, executive compensation votes, and auditor ratification. These disclosures provide formal records of Neogen’s public-company reporting, operating updates, governance structure and shareholder matters.
Neogen Corporation executive Tamara A. Ranalli filed an initial ownership report as a Senior Vice President of the company. The Form 3 states that no Neogen securities are beneficially owned, meaning she reported holding no direct or indirect shares or derivative securities of the company as of the event date of 01/07/2026.
Neogen Corporation insider reporting shows an indirect purchase of company stock linked to its CEO. On January 16, 2026, an account held by the CEO’s son bought 137 Common Shares of Neogen at $9.3349 per share. After this trade, that account held 632 Common Shares in total. The transaction is reported as indirect ownership "By son", and the reporting person, CEO and director Nassif Mikheal, explicitly disclaims beneficial ownership of these securities.
Neogen Corporation filed a current report to disclose that it has released financial results for its fiscal 2026 second quarter, which ended on November 30, 2025. The company furnished a press release, dated January 8, 2026, as Exhibit 99.1 to provide details about its results of operations and financial condition for this period. The information in this report and the attached press release is being furnished rather than filed, meaning it is not incorporated by reference into other regulatory documents.
Neogen Corp (NEOG) reported an insider transaction on a Form 4. A company insider who is both a Director and CEO reported an open‑market purchase (code P) of 177 common shares at $6.25 on 11/03/2025.
Following this transaction, the filing lists 495 shares beneficially owned, reported as Indirect (I) by son. The filing includes a standard disclaimer that the reporting person disclaims beneficial ownership of these indirectly held securities.
NEOGEN CORP CEO Nassif Mikheal filed an amended Form 3 reporting indirect holdings of company common shares held by his son. The amendment lists two indirect positions of 318 and 302 common shares as of August 11, 2025. A footnote states that Mikheal disclaims beneficial ownership of these securities, meaning he does not acknowledge them as his own holdings for Section 16 or other purposes.
Neogen (NEOG) reported an insider equity transaction by its CFO. On 11/03/2025, the officer acquired 178,855 shares of common stock at a stated price of $6.29, bringing directly held common shares to 178,855. The filing also shows a grant of stock options for 459,713 shares with an exercise price of $6.29.
According to the footnotes, the options vest in equal annual installments over three years from the grant date, while the performance stock units vest in total at the end of the three-year anniversary of the grant.
NEOGEN Corp (NEOG) reported an initial beneficial ownership filing for its Chief Financial Officer on Form 3. The filing states the officer is an Officer (Chief Financial Officer) and that the form was filed by one reporting person.
No securities are beneficially owned, according to the “Explanation of Responses.” The event requiring the statement occurred on 11/03/2025.
Neogen Corporation appointed Bryan Riggsbee as Senior Vice President and Chief Financial Officer, effective November 3, 2025, reporting to President and CEO Mike Nassif. Riggsbee previously served as CFO, North America at bioMérieux and spent nearly a decade as CFO at Myriad Genetics, with earlier finance roles at LabCorp, GE, and KPMG.
His compensation includes a $600,000 base salary, target annual bonus at 80% of salary under the ICP, and an annual long‑term equity grant targeted at $2,000,000. He will receive a one‑time equity inducement of $2,250,000 (50% stock options vesting ratably over three years and 50% PSUs aligned with the FY26 PSU Plan) and a $250,000 cash sign‑on payable by December 31, 2025, subject to repayment if employment ends within one year. He will relocate to Michigan within 24 months with customary relocation benefits and applicable repayment provisions.
Neogen Corp (NEOG) reported a director’s equity transaction. On 10/27/2025, 1,777 restricted stock units (RSUs) vested and were settled into an equal number of common shares via transaction code M. The non-derivative table shows 1,777 shares acquired at a listed price of $6.19. Following the transaction, the reporting person beneficially owned 96,347 shares directly. Remarks confirm each RSU equals one share and that the RSUs vested and were settled on the same date.